N/A N=92 Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand
Volume Deficit in the Hand
Primary: Responder Rate Using Validated Hand Grading Scale — 73; 18; 12; 67 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=409 Smoking Cessation Intervention in Public Housing
Cigarette Smoking
Primary: Number of Participants Abstinent From Smoking — 10; 24 Participants
N/A N=12 SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy
Lung Carcinoma · Malignant Neoplasm
Primary: Spatial Stability of Lung Perfusion and Ventilation Over Time, as Assessed Using 99mTc-MAA SPECT/CT — 0.95 correlation coefficient
Phase 3 N=58 Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment
Hunter Syndrome
Primary: Change From Baseline in the Differential Ability Scales, Second Edition (DAS-II) General Conceptual Ability (GCA) Standard Score at Week 52 — -7.4; -4.4 Score on a scale…
N/A N=130 Evaluation of Approved and Investigational Contact Lenses
Visual Acuity
Primary: Overall Comfort — 67.509; 61.185 Units on a Scale
Phase 2 N=27 Effects of Oxytocin Nasal Spray on Social Affiliation
Schizophrenia
Primary: Social Affiliation Measured by Social Affiliative Role Play — 4.026; 4.111; 4.079; 4.194 units on a scale — p=0.758
Phase 3 N=478 Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Progression Free Survival — 7.6; 11.2 months — p=0.0014
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
Phase 3 N=792 Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) Time in Programmed Death Ligand 1 (PD-L1) + Full Analysis Set Population (FAS) — 11.4; 10.6 months — p== 0.0721
N/A N=771 Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains
Streptococcus Agalactiae Infection
Primary: Performance Characteristics — 95.9; 95.5 percentage of specimens
Phase 1 N=30 StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
Skin Wound · Burns · Trauma-related Wound
Primary: Number of Participants With Wound Closure of the Treatment Sites at Three Months — 29; 29 Participants
Phase 2 N=12 Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients
Mucopolysaccharidosis (MPS)
Primary: Number of Treatment Emergent Serious Adverse Events (SAE) — 5; 3; 2 events
N/A N=154 PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
Overactive Bladder
Primary: Change in Number of Urinary Urge Incontinence (UUI) Episodes Per Day After the 12th PTNM Therapy Sessions From Baseline — -2.4 UUI episodes per day — p=<0.0001
N/A N=50 Comparative Effectiveness Between Microprocessor Knees and Non-Microprocessor Knees
Lower Limb Amputation Above Knee (Injury)
Primary: Daily Activity Measured With Triaxial Accelerometers — 15.64; 19.68; 18.23 % of Day — p=0.01
N/A N=300 Air Barrier System for the Prevention of Surgical Site Infection
Surgical Site Infection
Primary: Incidence of Implant Infection (Number of Occurrences in Each Arm). — 4; 0 Participants — p=0.067